

Supplementary material

Table S1. Overview of previously reported and overlapping analyses.

Sub-population	Treatment arm	Similar/overlapping data previously reported?
Composite responders		
Age	Placebo	Lembo AJ et al. <i>N Engl J Med</i> 2016; 374: 242–253 (Figure S3; weeks 1–26 responder n numbers in pooled population)
	ELX 75 mg	No
	ELX 100 mg	Lembo AJ et al. <i>N Engl J Med</i> 2016; 374: 242–253 (Figure S3; weeks 1–26 responder n numbers in pooled population)
Sex	Placebo	Lembo AJ et al. <i>N Engl J Med</i> 2016; 374: 242–253 (Figure S3; weeks 1–26 responder n numbers in pooled population)
	ELX 75 mg	No
	ELX 100 mg	Lembo AJ et al. <i>N Engl J Med</i> 2016; 374: 242–253 (Figure S3; weeks 1–26 responder n numbers in pooled population)

Sub-population	Treatment arm	Similar/overlapping data previously reported?
Composite responders		
Race	Placebo	No
	ELX 75 mg	No
	ELX 100 mg	No
BMI	Placebo	No
	ELX 75 mg	No
	ELX 100 mg	No
History of depression	Placebo	No
	ELX 75 mg	No
	ELX 100 mg	No
History of GERD	Placebo	No
	ELX 75 mg	No
	ELX 100 mg	No
IBS symptom history	Placebo	No
	ELX 75 mg	No

Sub-population	Treatment arm	Similar/overlapping data previously reported?
Composite responders		
	ELX 100 mg	No
Baseline pain	Placebo	No
	ELX 75 mg	No
	ELX 100 mg	No
Abdominal pain responders and stool consistency responders		
Age	Placebo	No
	ELX 75 mg	No
	ELX 100 mg	No
Sex	Placebo	No
	ELX 75 mg	No
	ELX 100 mg	No
BMI, body mass index; ELX, eluxadoline; GERD, gastroesophageal reflux disease; IBS, irritable bowel syndrome.		

Table S2. Composite endpoint responder proportions over weeks 1–26 by baseline demographics: pooled phase 3 studies.

	Placebo (<i>n</i> = 809)	ELX 75 mg (<i>n</i> = 808)	ELX 100 mg (<i>n</i> = 806)
Race			
White			
<i>n</i>	699	699	686
Responders, <i>n</i> (%)	139 (19.9)	193 (27.6)	219 (31.9)
Black			
<i>n</i>	89	92	96
Responders, <i>n</i> (%)	17 (19.1)	21 (22.8)	26 (27.1)
Other			
<i>n</i>	21	17	24
Responders, <i>n</i> (%)	2 (9.5)	2 (11.8)	5 (20.8)
BMI			
<30 kg/m ²			
<i>n</i>	428	430	418
Responders, <i>n</i> (%)	89 (20.8)	133 (30.9)	124 (29.7)
≥30 kg/m ²			
<i>n</i>	379	377	386
Responders, <i>n</i> (%)	69 (18.2)	83 (22.0)	126 (32.6)

Intention-to-treat analysis set, defined as all patients randomly assigned to treatment.

BMI, body mass index; ELX, eluxadoline.